Stockreport

Intellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA Filing [Yahoo! Finance]

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
PDF mean monthly attacks (0.26 vs 2.1) and 62% of lonvo-z patients were attack-free versus 11% on placebo. Lonvo-z is a one-time outpatient in vivo CRISPR therapy designed [Read more]